

83 15. (Amended) The lymphocyte according to claim 13 wherein the allogeneic agent is peripheral blood cells.

84 40. (Amended) A pharmaceutical composition comprising:
a population of lymphocytes containing a chimeric receptor reactive with a tumor antigen and preselected for reactivity with a strong antigen, wherein the strong antigen is an allogeneic agent; and
a pharmaceutically acceptable carrier.

41. (Amended) A method of preparing preselected dual specificity lymphocytes comprising:
selecting for lymphocytes reactive with a strong antigen ex vivo, wherein the strong antigen is an allogeneic agent; and
transducing the lymphocytes with a chimeric receptor gene, said gene encoding a receptor which is reactive with a tumor antigen.

REMARKS

The Present Invention

The present invention pertains to lymphocytes having dual antigen-specificity, compositions comprising the same, a pharmaceutical composition comprising the same, and a method of preparing the same.

The Pending Claims

Claims 1, 3-8, 10-12, 15, 40, 41, and 43 are pending. Claims 1, 3-8 and 10 are directed to a composition comprising a preselected population of lymphocytes. Claim 11 is directed to a lymphocyte having a T-cell receptor reactive with an allogeneic agent and a chimeric receptor reactive with a tumor antigen. Claims 12 and 15 are directed to a lymphocyte comprising a T-cell receptor reactive with a strong antigen and a chimeric receptor reactive with a tumor antigen. Claim 40 is directed to a pharmaceutical composition comprising a population of lymphocytes. Claims 41 and 43 are directed to a method of preparing preselected dual specificity lymphocytes.

The Office Action

The Office has objected to the specification, as the status of U.S. Patent Application No. 08/547,263, which is cited on page 17, line 2, allegedly needs to be updated. Claims 1-4, 6-8, 10-13, 15, and 40-43 have been rejected under 35 U.S.C. §